Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jennifer Sherr MD, PhD

Jennifer L. Sherr MD, PhD

Professor of Pediatrics, Pediatric Endocrinology, Yale University School of Medicine, New Haven, Connecticut

Dr. Jennifer Sherr is an Instructor in Pediatrics (endocrinology) at Yale University School of Medicine. She attended the University of Medicine and Dentistry New Jersey-Robert Wood Johnson Medical School and subsequently came to Yale Children’s Hospital to complete her pediatric residency.

During her fellowship in endocrinology at Yale University School of Medicine, she was accepted into the Investigate Medicine Program at Yale University Graduate School of Arts & Sciences. The focus of her doctoral thesis was examination of the dysregulated glucagon response early in the course of type 1 diabetes.

Subsequently, her research has focused on artificial pancreas technologies and the use of adjunctive therapy to mitigate postprandial hyperglycemia.


Degrees:

MD: University of Medicine and Dentistry New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ

PhD: Investigative Medicine at Yale University Graduate School of Arts & Sciences


Postgraduate Training:

Residency: Yale New Haven Children’s Hospital Residency Program

Fellowship: Yale University School of Medicine Postdoctoral Fellowship in Pediatric Endocrinology and Metabolism

Research Interests: closed loop systems/artificial pancreas technologies, counterregulatory responses to hypoglycemia, use of adjunctive therapy for type 1 diabetes.

Disclosures

Dr. Sherr has received grants or contracts from JDRF, National Institute of Diabetes and Digestive and Kidney Diseases, Jaeb Center for Health Research, Insulet, Medtronic, Provention Bio, and Abbott paid to her institution; has received consulting fees from Abbott; has received payment or honoraria from Insulet, Medtronic Diabetes, and Zealand Pharma; has participated in advisory boards for Cecelia Health, Insulet, Mannkind, Medtronic Diabetes, and Vertex Pharmaceuticals; and reports owning stock/stock options of StartUp Health T1D Moonshot.

Recent Contributions to PracticeUpdate:

  1. Implications of Continuous Ketone Monitoring in Clinical Practice
  2. Treatment of Gestational Diabetes Diagnosed Early in Pregnancy
  3. Fixed-Dose Coadministration of Pramlintide Plus Regular Insulin Shows Promise for Postprandial Hyperglycemia
  4. Insulin Infusion and Glucose Monitoring: A Guideline for Diabetes Technologies
  5. Improved Glycemic Control With Closed-Loop Insulin in Pregnant Diabetic Women
  6. Intranasal Glucagon for Insulin-Induced Hypoglycemia in Type 1 Diabetes
  7. Risk Factors Associated With Mortality During Early Adulthood in Type 1 Diabetes

Most Read This Week

Recently Updated